Skip NavigationSkip to Content
Return Return to Search Results

Urinary Estrogen Metabolites and Prostate Cancer Risk: A Pilot Study

  1. Author:
    Kosti, O.
    Xu, X.
    Veenstra, T. D.
    Hsing, A. W.
    Chu, L. W.
    Goldman, L.
    Bebu, I.
    Collins, S.
    Dritschilo, A.
    Lynch, J. H.
    Goldman, R.

  2. Author Address

    [Goldman, Radoslav] Georgetown Univ, Dept Oncol, LCC, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA. [Xu, Xia; Veenstra, Timothy D.] NCI, Lab Prote & Analyt Technol, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21701 USA. [Hsing, Ann W.; Chu, Lisa W.] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Bethesda, MD 20892 USA. [Bebu, Ionut] Georgetown Univ, Dept Biostat Bioinformat & Biomath, Washington, DC 20057 USA. [Collins, Sean; Dritschilo, Anatoly] Georgetown Univ Hosp, Washington, DC 20007 USA. [Lynch, John H.] Georgetown Univ, Dept Urol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA.;Goldman, R, Georgetown Univ, Dept Oncol, LCC, Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd NW,S183, Washington, DC 20057 USA.;rg26@georgetown.edu
    1. Year: 2011
    2. Date: Apr
  2. Journal: Prostate
    1. 71
    2. 5
    3. Pages: 507-516
  4. Type of Article: Article
  5. ISSN: 0270-4137
  1. Abstract:

    BACKGROUND. The high incidence of and few identified risk factors for prostate cancer underscore the need to further evaluate markers of prostate carcinogenesis. The aim of this pilot study was to evaluate urinary estrogen metabolites as a biomarker of prostate cancer risk. METHODS. Using a liquid chromatography-tandem mass spectrometry method, urinary concentrations of 15 estrogen metabolites were determined in 77 prostate cancer cases, 77 healthy controls, and 37 subjects who had no evidence of prostate cancer after a prostate biopsy. RESULTS. We observed an inverse association between the urinary 16-ketoestradiol (16-KE2) and 17-epiestriol (17-epiE3)-metabolites with high estrogenic activity-and prostate cancer risk. Men in the lowest quartile of 16-KE2, had a 4.6-fold risk of prostate cancer (OR = 4.62, 95% CI = 1.34-15.99), compared with those in the highest quartile. CONCLUSIONS. We observed modest differences in estrogen metabolite concentrations between prostate cancer patients and subjects without cancer. Larger studies with both androgen and estrogen measurements are needed to confirm these results to clarify further whether estrogen metabolites are independent biomarkers for prostate cancer risk and whether androgen/estrogen imbalance influences prostate cancer risk. Prostate 71: 507-516, 2011. (C) 2010 Wiley-Liss, Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/pros.21262
  3. View record in Web of Science®
  4. WOS: 000288135700008

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel